Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-EPOCH vs R-CHOP for AIDS-associated CD20+ diffuse large B-cell lymphoma
ChiCTR-OPC-16010056Phase 4Recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: progression-free survival. Started Dec 2016; status: recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR-OPC-16010056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16010056.